RCRobert J. Casson

Robert J. Casson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert J. Casson has a total of 316 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the Safety and Therapeutic Range of Nanosecond Laser Treatment in Rabbits

    by Glyn Chidlow, John P. M. Wood, Weng Onn Chan, Robert J. Casson

    Background: Subthreshold, nanosecond laser therapy has potential as a treatment for age‐related macular degeneration; however, the therapeutic range and safety profile have not been fully documented. In this study, rabbits were used for a preclinical assessment of nanosecond laser treatment. Methods: Adult pigmented rabbits received nanosecond laser treatment at a range of ophthalmoscopically visible and subthreshold energy settings. Various parameters were investigated following laser treatment, namely ophthalmoscopic visibility, haemorrhage, near‐infrared (NIR) fundus visibility, angiographic visibility and structure of the retina/retinal pigment epithelium (RPE) as determined by spectral domain optical coherence tomography and post‐mortem histology. Results: Ophthalmoscopically visible energy settings, namely visual effect threshold (VET) and 150% of VET, caused ablation and renewal of targeted RPE cells. These settings presented no vascular damage or Bruch's membrane rupture, but localised photoreceptor loss was evident. A clinically relevant subthreshold energy setting, determined as 50% of VET, likewise caused ablation and renewal of RPE cells. While this setting caused no photoreceptor loss, disruption to segments overlying lesions was evident, which resolved over time. Application of the laser at 25% of VET also caused ablation of RPE cells, while reduction to 12.5% of VET elicited predominantly sublethal injury. The lowest energy setting (8% of VET) had no discernible effect upon RPE cells. The three lower subthreshold energy settings caused no photoreceptor injury. Conclusions: Nanosecond laser treatment can be used at lower irradiances than previously employed without causing disruption to photoreceptor segments. The use of this lower energy setting in clinical trials is worthy of consideration.

  • Open Access

    Monitoring Reactive Oxygen Species‐Induced Cellular Responses in Retinal Pigment Epithelium Cells Using Autofluorescence Multispectral Imaging

    by Abhilash Goud Marupally, Aline Knab, Ayad G. Anwer, Yuan Tian, Shannon Handley, Abbas Habibalahi, Andrew White, Nicole Carnt, Robert Casson, Ewa M. Goldys

    Oxidative stress is implicated in several ocular diseases including age‐related macular degeneration, cataracts, and glaucoma, where disease‐associated cellular alterations may provide insights into underlying metabolic changes. This study investigated the potential of autofluorescence multispectral imaging (AFMI) to detect reactive oxygen species (ROS)‐associated cellular responses in a retinal pigment epithelial (RPE) cell culture model. RPE cells were exposed to five agents inducing oxidative stress through distinct mechanisms: glycolytic inhibition (iodoacetic acid), mitochondrial dysfunction (rotenone), endoplasmic reticulum stress (thapsigargin), direct oxidative stress (hydrogen peroxide), and excitotoxicity ( N ‐methyl‐D‐aspartate). ROS generation was confirmed using dihydroethidium (DHE) staining. Spectral autofluorescence images of unstained cells were acquired across 33 excitation–emission wavelength combinations. Spectral features were derived from individual cells, and the three most informative features were used to train a logistic regression classifier to distinguish treated from control cells. Analyses, including the optical redox ratio (ORR), were performed using both the full spectral range and a subset of UV‐free excitation channels. All stressors produced a dose‐dependent reduction in cell viability and significantly increased ROS levels compared with controls. Four of the five stress conditions produced significant differences in ORR. Classification performance varied by stress mechanism, with the highest performance observed for mitochondrial stress (AUC = 0.90 ± 0.05). Overall, AFMI enabled non‐invasive detection of ROS‐associated cellular responses in RPE cells. Accurate classification using UV‐free excitation supports its potential for clinical translation.

  • Open Access

    Assessing oxidative stress in retinal tissue using multispectral autofluorescence imaging

    by Aline Knab, Abhilash Goud Marupally, Ayad G. Anwer, Abbas Habibalahi, Ushasree Pattamatta, Nicole Carnt, Robert Casson, Ewa M. Goldys, Andrew White

  • Open Access

    Predictive Performance of Polygenic Risk Scores for Primary Open-Angle Glaucoma: A Systematic Review and Meta-Analysis

    by Asmaa A. Zidan, Abdullah Ahmed, Shahid Ullah, Robert Casson

  • Open Access

    Photopharmacology: A new paradigm for vision restoration

    by Robert J. Casson

  • Open Access

    National Income and Time-Related Changes in Childhood Blindness: A 50-Year Systematic Review and Meta-Analysis

    by Thomas Rogerson, Alexandra Murray, Robert J. Casson

    Background: The relationship between socioeconomic development and the prevalence and causes of childhood blindness has not been systematically quantified globally; we assessed income-related and temporal variation in its prevalence and aetiologyMethods: We conducted a systematic review and random-effects meta-analysis of studies reporting the prevalence and causes of childhood blindness and severe visual impairment (SVI) in individuals younger than 16 years, defined by ICD-11 criteria. MEDLINE, Embase, PubMed, and the Cochrane Database of Systematic Reviews were searched from Jan 1, 1970, to May 22, 2021. Eligible studies reported prevalence or causes of blindness or SVI; studies without clear visual acuity definitions or reporting single causes were excluded. Two reviewers independently screened studies, extracted data, and assessed risk of bias using Joanna Briggs Institute criteria. The primary outcomes were prevalence of blindness and proportional causes by income group and period. Pooled estimates were generated using random-effects meta-analysis. The protocol was registered with PROSPERO (CRD42022361015).Findings: There were 91 studies from 52 countries included, comprising 22 297 children with blindness for aetiological analyses and 8 548 555 children for prevalence analyses. The prevalence of childhood blindness differed by income group (p = 0·015), with the highest prevalence in middle-income countries (130·2 per 100 000 children) compared with low-income (64·0) and high-income countries (42·2). We estimated that 1·93 million children are blind globally, of whom 80·7% reside in low- and middle-income countries. Causes varied by income: anterior segment causes predominated in low-income settings, whereas posterior segment and visual pathway disorders were more common in higher-income settings. Substantial heterogeneity was observed across studies (I² > 75% for most analyses).Interpretation: Childhood blindness follows a development-associated epidemiological transition, with a shift from avoidable anterior segment disease to retinal and neurodevelopmental causes as countries undergo economic growth.

  • Top Cited Papers
    Open Access

    Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial

    by Robert J. Casson, Eric Daniels, Christen D. Barras, Andrew Dwyer, Brian M. Strem, Charles C. Wykoff, Claudia Gregorio-King, Cameron Schuh, Richard H. Kramer, Russell N. Van Gelder

    A small azobenzene photoswitch molecule (KIO-301), designed to confer light responsiveness to retinal ganglion cells, was evaluated for safety and feasibility in a first-in-human, phase 1, gene-agnostic, open-label, dose-escalation clinical trial in individuals with advanced retinitis pigmentosa (RP). KIO-301 was administered by intravitreal injection to 12 eyes of 6 participants. The primary outcome was ocular and systemic safety over 30 days. Secondary and exploratory assessments included functional vision testing, visual acuity, kinetic visual field, functional magnetic resonance imaging and participant-reported outcomes. The primary safety outcome was met, with no serious adverse events or dose-limiting toxicities observed at any point. No drug-related intraocular inflammation occurred, and all ocular adverse events were mild and procedure-related. Exploratory assessments identified variation in light perception and functional vision measures in some participants. Light-evoked blood-oxygen-level-dependent signal changes in visual cortical regions were observed following dosing and showed a temporal pattern compatible with pharmacodynamic activity. Participant-reported quality-of-life scores varied over time. In this small, nonrandomized phase 1 study in individuals with late-stage RP, intravitreal KIO-301 demonstrated an acceptable safety and tolerability profile, supporting the feasibility of photoswitch therapy in advanced RP, and motivating further evaluation in larger trials. ClinicalTrials.gov identifier: NCT05282953


  • Open Access

    Vision restoration using a light-responsive small molecule photoswitch (KIO-301) in advanced retinitis pigmentosa: the ABACUS-1 phase 1/2 clinical trial

    by Robert Casson, Eric Daniels, Christen Barras, Andrew Dwyer, Brian Strem, Charles Wykoff, Claudia Gregorio-King Gregorio-King, Cameron Schuh, Richard Kramer, Russell Van Gelder

    A small, azobenzene, photoswitch molecule (KIO-301) that renders retinal ganglion cells responsive to light was investigated for safety and activity in a first-in-human, phase 1/2, open-label, dose-escalation clinical trial in individuals with advanced retinitis pigmentosa. KIO-301 was delivered by intravitreal injection to 12 eyes of 6 participants. The primary endpoint was safety. Secondary endpoints included assessment of functional vision, visual acuity, kinetic visual field, functional magnetic resonance imaging (fMRI) and participant reported outcomes. There were no drug-related adverse events. A participant with no light perception at baseline recovered light perception by 2 days post injection. Visual function, including navigational ability, displayed a trend of improvement. By day 2-14 post injection the fMRI signal to visual stimuli in the primary visual cortex was enhanced and decayed over the ensuing 3 weeks. Participant-reported quality of life improved. The excellent safety profile and evidence supporting proof-of-principle has motivated a larger, randomized controlled trial.


  • Open Access

    A Multitrait Polygenic Risk Score for Open-Angle Glaucoma Stratifies Risk of Pigmentary Glaucoma in Pigment Dispersion Syndrome

    by Antonia Kolovos, Ayub Qassim, Henry N. Marshall, Thi Thi Nguyen, Joshua Schmidt, Mark M. Hassall, Victoria Tang, Giorgina Maxwell, John Landers, Richard Mills, et al.